Price Alert

ImmuCell Corporation (ICCC)

NASDAQ: ICCC · Real-Time Price · USD

6.09

-0.63 (-9.38%)

At close: Aug 15, 2025, 3:59 PM

6.19

1.64%

After-hours: Aug 15, 2025, 04:10 PM EDT

-9.38% (1D)

Bid	5.75
Market Cap	55.04M
Revenue (ttm)	8.09B
Net Income (ttm)	1.45B
EPS (ttm)	-0.04
PE Ratio (ttm)	-152.25
Forward PE	-60.55
Analyst	n/a

Ask	7.38
Volume	32,519
Avg. Volume (20D)	26,127
Open	6.76
Previous Close	6.72
Day's Range	5.92 - 6.76
52-Week Range	3.34 - 7.60
Beta	0.31

About ICCC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ICCC

Website n/a

Full Company Profile

Why Price Moved

1 day ago New

ImmuCell shares are trading lower following the re... Unlock content with Pro Subscription

1 month ago

-10.76%

ImmuCell shares are trading lower. The company announced it will commence a CEO and president succession plan amid its current CEO's plan to retire in 2026.

News

1 day ago · seekingalpha.com

ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q2 2025 Earnings Conference Call August 15, 2025 9:00 AM ET Company Participants Michael F. Brigham - President, CEO, Treasurer, Secretary & Director Timothy C.

3 weeks ago · zacks.com

ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside

ICCC earns "Outperform" rating with record Q1 sales, margin gains and growth potential tied to Re-Tain's FDA progress and new product formats.

2 months ago · zacks.com

ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

ICCC posts record Q1 sales, returns to earnings and expands margins y/y as First Defense demand grows and production issues subside.

3 months ago · seekingalpha.com

ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President & Chief ...